EMA seeks executive director

Andreas Pott will be acting executive director until position is filled

The European Medicines Agency (EMA) is seeking a new executive director. Its current head, Thomas Lönngren, is leaving the post on 31 December, following the end of his second five-year mandate.

While EMA searches for a permanent replacement, its current head of administration, Andreas Pott, will serve as acting executive director.

University of Hamburg graduate, Pott has been the agency’s administration chief since 2000, having previously worked for the European Parliament and the EU’s translation service.

Swede Lönngren is a former deputy director-general of the Swedish Medical Products Agency (MPA).

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Drug Delivery

Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies

The fixed-dose, multi-use pull-push device accommodates volumes up to 0.75 mL, offering pharma partners a scalable, error-reducing delivery solution for diabetes and weight management programmes
Finance

GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors

GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
Finance

UK healthcare M&A drops 26% in Q1 2026 amid geopolitical tension and financing pressures

Heligan Group's latest report records just 53 deals, down from 72 in Q1 2025, with pharma and life sciences remaining most active despite tighter financing conditions and prolonged deal timelines
You need to be a subscriber to read this article.
Click here to find out more.
Finance

ADC funding, spatial biology investment and haematology M&A signal biopharma pipeline momentum

From a $86.6m Series B for first-in-class ADCs to a $1.25bn haematology acquisition, this week's deals reflect sustained biopharma investment in next-generation therapeutic platforms
Subscribe now